XFOR

X4 is a pre-profitability, single-asset biotech whose entire equity value rests on one unresolved event: the 4WARD Phase 3 trial of mavorixafor in chronic neutropenia, which won't even complete enrollment until Q3 2026 and runs 52 weeks per patient thereafter. The one approved product, XOLREMDI for WHIM syndrome, is being actively deprioritized ('we are no longer prioritizing investment in the WHIM indication'), so the FY2025 revenue of $35.1M — however eye-catching the +1273% jump looks — is not a durable, growing commercial base; it is the byproduct of a franchise management is walking away from. Operating margin is -247%, net margin -226%, and the company burned $85.6M of operating cash in the year. This is a story stock, not a going concern that stands on its numbers.

The balance sheet buys time but at brutal cost to shareholders. Cash of $217M against ~$86M annual burn implies roughly 2–2.5 years of runway, likely enough to reach full enrollment but not a clean Phase 3 readout without raising again. Getting there required stacking financings: an $81.0M private placement in Q3 2025 and a $145.6M underwritten offering in October 2025, on top of pre-funded warrants. The accumulated deficit is -$595M and management executed two workforce cuts in 2025 (~30% then ~50%), closed the Vienna R&D site, and paused preclinical programs — a company shrinking itself to survive to one data point. The ~48% drop in share count alongside massive capital raises signals a reverse split, a classic distress marker retail investors should not overlook.